We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

6 hedge funds and large institutions have $5.59M invested in Seelos Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

20% more funds holding

Funds holding: 5 → 6 (+1)

7% less capital invested

Capital invested by funds: $6.01M → $5.59M (-$423K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.14%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HVC
Healthcare Value Capital
New Jersey
+$200K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.2M
2
FANJ
Financial Architects (New Jersey)
New Jersey
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Sarissa Capital Management
Connecticut
$2.66M – – –
AC
2
Armistice Capital
New York
$1.56M -$1.2M -6 -46%
Vanguard Group
3
Vanguard Group
Pennsylvania
$541K – – –
HVC
4
Healthcare Value Capital
New Jersey
$184K +$200K +1 New
BlackRock
5
BlackRock
New York
$161K – – –
Franklin Resources
6
Franklin Resources
California
$139K – – –
BIP
7
Brandes Investment Partners
California
$64K – – –
OAM
8
Oxford Asset Management
United Kingdom
$53K – – –
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$47K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$45K – – –
Northern Trust
11
Northern Trust
Illinois
$28K – – –
Citadel Advisors
12
Citadel Advisors
Florida
$22K – – –
Bank of New York Mellon
13
Bank of New York Mellon
New York
$21K – – –
VF
14
Virtu Financial
New York
$21K – – –
CF
15
Centaurus Financial
California
$18K – – –
EWM
16
Evercore Wealth Management
New York
$5K – – –
Citigroup
17
Citigroup
New York
$4K – – –
Wells Fargo
18
Wells Fargo
California
$2K – – –
FDCDDQ
19
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.29K – – –
AG
20
Advisor Group
Arizona
$1K – – –
Group One Trading
21
Group One Trading
Illinois
$1K – – –
JP Morgan Chase
22
JP Morgan Chase
New York
$1K – – –
UBS Group
23
UBS Group
Switzerland
$1K – – –
FANJ
24
Financial Architects (New Jersey)
New Jersey
– -$3K – –

SEEL Hedge Fund Activity: Q4 2017 in Review

6 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2017, worth a combined $5.59M — down 7% from $6.01M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new SEEL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Healthcare Value Capital, opening a new position worth an estimated $200K. The largest seller was Armistice Capital, cutting an estimated $1.2M.

  • 6 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2017, up from 5 in Q3 2017.
  • Funds reported $5.59M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2017, down 7% quarter-over-quarter.
  • 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2017 and 0 closed out, a net change of +1 holder.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2017 was Healthcare Value Capital, an estimated $200K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2017 was Armistice Capital, an estimated $1.2M sold.

Based on aggregated 13F filings for Q4 2017.